PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Обратная связь
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться
  1. Биоэквивалентность. ANOVA. Часть I.
  2. Биоэквивалентность. ANOVA. Часть II.
  3. Биоэквивалентность. ANOVA. Пример.
  4. Phoenix WinNonlin проект подтверждения метода.
  5. Биоэквивалентность. Расчет выборки.
  6. Пример расчета выборки с помощью итеративной процедуры.
  7. Пример расчета pooled CV и доверительного интервала для CV.
  8. Фармакокинетика. Основные понятия.
  9. Фармакокинетика. Основные понятия. Пример расчета ФК параметров.
  10. Phoenix WinNonlin проект подтверждения примера расчета ФК параметров.
  11. Планирование клинического исследования.
  12. Биоэквивалентность. ANOVA. Часть III.
  13. Таблица данных для тестового расчета.

Свежие записи

  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0
  • ClinicalTrialUtilities: обзор

Галерея

DJI 0060
20180814 165255
DJI 0030
20180128 180845
DJI 0014
20170802 183936
  • Spikevax and Moderna COVID-19 Vaccine
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-07-01 By FDA
  • Pulmonary-Allergy Drugs Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Patient Labeling Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Human medicines European public assessment report (EPAR): Uptravi, selexipag, Hypertension, Pulmonary, Date of authorisation: 12/05/2016, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung;Breast Neoplasms;Ovarian Neoplasms;Colorectal Neoplasms;Carcinoma, Renal Cell, Date of authorisation: 12/01/2005, Revision: 60, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Anxiety Disorders;Neuralgia;Epilepsy, Date of authorisation: 19/06/2015, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Executive Careers at CDER
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Human medicines European public assessment report (EPAR): Cuprymina, copper (64Cu) chloride, Radionuclide Imaging, Date of authorisation: 23/08/2012, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Epilepsy, Date of authorisation: 03/10/2011, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Pregabalin Sandoz GmbH, pregabalin, Anxiety Disorders;Epilepsy, Date of authorisation: 19/06/2015, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Zostavax, shingles (herpes zoster) vaccine (live), Herpes Zoster;Immunization, Date of authorisation: 19/05/2006, Revision: 33, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), COVID-19 virus infection, Date of authorisation: 24/06/2022, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Ristfor, sitagliptin,metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Rydapt, midostaurin, Leukemia, Myeloid, Acute;Mastocytosis, Date of authorisation: 18/09/2017, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
Предыдущие записи
Тема: Scaffold от Danny Cooper.